New release allows users to solve problems that were previously out of reach, run more scenarios, and get feasible solutions ...
Researchers developed a label-partitioned tree decomposition and parameter-separated index that cuts path query latency and ...
In 1984, Narendra Karmarkar revolutionized linear programming with a new algorithm that improved efficiency in resource ...
A major phase 3 clinical trial was widely expected to confirm the lipoprotein(a) [Lp(a)] hypothesis — that lowering it yields cardiovascular benefit. Harpreet Bhatia, MD When the disappointing results ...
On this date in 1999, Wu-Tang Clan heavyweight Method Man and Def Squad standout Redman joined forces for the release of their first full-length collaborative album, Blackout!, through Def Jam ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Emerging venture managers increasingly value smaller family office commitments over large ...
The much-anticipated Lp(a)HORIZON trial testing whether the novel drug pelacarsen can improve cardiovascular outcomes by decreasing lipoprotein(a) levels has failed to meet its primary endpoint.
Novartis’ pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.
Please provide your email address to receive an email when new articles are posted on . Pelacarsen did not reduce cardiovascular events in patients with elevated lipoprotein(a) compared with placebo.
The result calls into question other late-stage trials testing Lp(a)-lowering drugs from the likes of Amgen and Eli Lilly. (iStock / Getty Images Plus) Novartis’ Ionis-partnered drug designed to lower ...
Elevated levels of lipoprotein(a) above 175 nmol/L is associated with increased cardiovascular risk, especially among patients with existing heart disease, and warrants aggressive treatment to reduce ...